JOHN OYLER - 06 Mar 2026 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Role
Chief Executive Officer, Director
Signature
/s/ Qing Nian, as Attorney-in-Fact
Issuer symbol
ONC
Transactions as of
06 Mar 2026
Net transactions value
$0
Form type
4
Filing time
10 Mar 2026, 20:14:25 UTC
Previous filing
17 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
OYLER JOHN Chief Executive Officer, Director C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND /s/ Qing Nian, as Attorney-in-Fact 10 Mar 2026 0001042047

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONC Ordinary Shares Award +326,976 +6.3% $0.000000* 5,491,339 06 Mar 2026 Direct F1
transaction ONC Ordinary Shares Award +117,936 +2.1% $0.000000* 5,609,275 06 Mar 2026 Direct F2
holding ONC Ordinary Shares 481,533 06 Mar 2026 See Footnote F3
holding ONC Ordinary Shares 7,699,158 06 Mar 2026 See Footnote F4
holding ONC Ordinary Shares 28,204,115 06 Mar 2026 See Footnote F5
holding ONC Ordinary Shares 9,545,000 06 Mar 2026 See Footnote F6
holding ONC Ordinary Shares 102,188 06 Mar 2026 See Footnote F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested shares are subject to accelerated vesting upon change of control or certain termination events.
F2 Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2028, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested shares are subject to accelerated vesting upon change of control or certain termination events.
F3 These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
F4 These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F5 These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F6 These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
F7 These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.